Quince Therapeutics (NASDAQ: QNCX) reported a second-quarter 2026 earnings per share (EPS) of $(12.31), significantly beating the analyst consensus estimate of $(26.32) by 53.21%. This performance marks an 81.9% improvement over the $(68.00) per share loss recorded in the corresponding period of 2025.

The financial results reflect the substantial non-cash charges associated with the merger and restructuring activities undertaken during the quarter, including the completion of its acquisition of Orphai Therapeutics and the closing of a concurrent private placement financing that yielded gross proceeds of $115 million. Despite the widened net loss on an absolute basis, the company’s balance sheet has been strengthened, with cash and cash equivalents reaching $116 million as of June 30, 2026. Management stated this position is expected to fund operations through the end of 2028.

Financial Performance

Total operating expenses for the three months ended June 30, 2026, were $79.8 million, up sharply from $10.4 million in Q2 2025. This increase was primarily driven by one-time charges related to the Orphai acquisition.

Research and development (R&D) expense decreased to $5.5 million from $6.6 million year-over-year. The reduction was attributed to the wind-down of the eDSP program, which offset an $0.8 million increase in costs for the LAM-001 program due to study start-up activities.

General and administrative (G&A) expense rose to $16.6 million from $3.3 million. This surge included $9.1 million in non-cash stock-based compensation resulting from the assumption of historical options upon the closing of the Orphai acquisition, along with a $4.4 million increase in professional fees linked to pre-acquisition restructuring.

What the Numbers Show

The reported net loss was heavily influenced by non-operational items. While total operating expenses increased by approximately $69.4 million year-over-year, this figure includes a $59.0 million charge for acquired in-process research and development and a $1.3 million gain on the Orphai acquisition. Excluding these specific acquisition-related items, the underlying operational burn rate saw a more moderate increase, driven largely by the G&A restructuring costs rather than core R&D expansion.

Pipeline and Corporate Updates

The acquisition of Orphai Therapeutics added LAM-001, an inhaled formulation of rapamycin, to Quince’s pipeline. LAM-001 is being developed for serious pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH).

Key clinical milestones include:

• Initiation of the Phase 2b trial of LAM-001 in PH-ILD, with topline data anticipated in the first quarter of 2028.
• Expectation of Phase 2 data in BOS in the first quarter of 2027.
• Planned initiation of a Phase 2 study in SAPH in late 2026, with data expected in the fourth quarter of 2028.

Additionally, Quince presented new Phase 2a data at the American Thoracic Society Conference, showing clinically meaningful improvements in functional and hemodynamic measures for patients with PAH and PH-ILD. The company also formed a Scientific Advisory Board comprising five experts in pulmonary medicine to guide the development of LAM-001.

Quince Therapeutics has conditionally appointed Brigette Roberts as Chief Executive Officer and John Militello as Chief Financial Officer. The leadership changes were disclosed in a filing submitted to the Securities and Exchange Commission (SEC). These appointments mark a significant shift in the company's executive management structure.

The filings confirm that both appointments are conditional, indicating that final confirmation may be subject to further regulatory or board processes not detailed in the immediate disclosure. No specific start dates or additional terms of employment were provided in the source document.

Executive Appointments

The new executive team members are:

Both individuals have been named to their respective roles on a conditional basis, as stated in the SEC filing. The company did not provide further details regarding the reasons for the appointments or the previous occupants of these roles.